Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cogent Biosciences, Inc. (COGT)

Cogent Biosciences signs five-year supply deal with Hovione for bezuclastinib

Neutral Impact 2 of 5 product/contract Written later

Cogent Biosciences entered into a Commercial Supply Agreement dated September 1, 2026 with Hovione FarmaCiencia S.A. to manufacture bezuclastinib spray-dried dispersion and tablets. The agreement sets a five-year initial term with automatic two-year renewals, giving the company a defined manufacturing relationship for its product.

Key points

  • Agreement dated September 1, 2026 with Hovione FarmaCiencia S.A. for bezuclastinib spray-dried dispersion and tablets
  • Initial term of five years, followed by automatic two-year renewals
  • Company buys minimum percentages of its requirements from Hovione, with percentages decreasing over the term
  • Full agreement to be filed as an exhibit to the 10-Q for the quarter ending September 30, 2026, with some information omitted

The filing

CompanyCogent Biosciences, Inc. (COGT)
Form8-K, current report
Filed with the SECSep 2, 2026, 4:11 PM ET
Accession number0001193125-26-380194

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.